Evidence map›Paper›PMID 25850001›Full record

ArticlePloS one2015

Continuing treatment with Salvia miltiorrhiza injection attenuates myocardial fibrosis in chronic iron-overloaded mice.

Ying Zhang, Hao Wang, Lijing Cui, Yuanyuan Zhang, Yang Liu, Xi Chu, Zhenyi Liu, Jianping Zhang, Li Chu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Exploring the anti‑oxidative mechanisms ofMolecular medicine reports · 2024
    Article
  3. Review
  4. Frontiers in pharmacology · 2022
    Review
  5. Article
  6. Article
  7. Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  8. Review
  9. Overview ofAntioxidants (Basel, Switzerland) · 2020
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ying ZhangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Hao WangDepartment of Chinese Materia Medica, Hebei Medical University, Shijiazhuang, China.
Lijing CuiDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Yuanyuan ZhangDepartment of Pharmaceutics, Hebei University of Chinese Medicine, Shijiazhuang, China.
Yang LiuDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Xi ChuThe Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhenyi LiuDepartment of Pharmaceutics, Hebei University of Chinese Medicine, Shijiazhuang, China.
Jianping ZhangDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Li ChuDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNHebei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron overload cardiomyopathy results from iron accumulation in the myocardium that is closely linked to iron-mediated myocardial fibrosis. Salvia miltiorrhiza (SM, also known as Danshen), a traditional Chinese medicinal herb, has been widely used for hundreds of years to treat cardiovascular diseases. Here, we investigated the effect and potential mechanism of SM on myocardial fibrosis induced by chronic iron overload (CIO) in mice. Kunming male mice (8 weeks old) were randomized to six groups of 10 animals each: control (CONT), CIO, low-dose SM (L-SM), high-dose SM (H-SM), verapamil (VRP) and deferoxamine (DFO) groups. Normal saline was injected in the CONT group. Mice in the other five groups were treated with iron dextran at 50 mg/kg per day intraperitoneally for 7 weeks, and those in the latter four groups also received corresponding daily treatments, including 3 g/kg or 6 g/kg of SM, 100 mg/kg of VRP, or 100 mg/kg of DFO. The iron deposition was estimated histologically using Prussian blue staining. Myocardial fibrosis was determined by Masson's trichrome staining and hydroxyproline (Hyp) quantitative assay. Superoxide dismutase (SOD) activity, malondialdehyde (MDA) content and protein expression levels of type I collagen (COL I), type I collagen (COL III), transforming growth factor-β1 (TGF-β1) and matrix metalloproteinase-9 (MMP-9) were analyzed to investigate the mechanisms underlying the effects of SM against iron-overloaded fibrosis. Treatment of chronic iron-overloaded mice with SM dose-dependently reduced iron deposition levels, fibrotic area percentage, Hyp content, expression levels of COL I and COL III, as well as upregulated the expression of TGF- β1 and MMP-9 proteins in the heart. Moreover, SM treatment decreased MDA content and increased SOD activity. In conclusion, SM exerted activities against cardiac fibrosis induced by CIO, which may be attributed to its inhibition of iron deposition, as well as collagen metabolism and oxidative stress.

Indexed as

AnimalsCollagen Type ICollagen Type IIIDeferoxamineDrugs, Chinese HerbalEndomyocardial FibrosisIronIron-Dextran ComplexIron OverloadMalondialdehydeMatrix Metalloproteinase 9Medicine, Chinese TraditionalMiceOxidative StressPlant ExtractsRandom AllocationCollagen Type ICollagen Type IIIdan-shen root extractDeferoxamineDrugs, Chinese HerbalIronIron-Dextran ComplexMalondialdehydeMatrix Metalloproteinase 9Mmp9 protein, mousePlant ExtractsSuperoxide DismutaseTransforming Growth Factor beta1Verapamil

Identifiers

PMID25850001
PMCPMC4388639
OpenAlexW2017270020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.